COVID-19 유행 시기의 조현병 환자 지원

키워드

참고문헌 (69)

1. Kim M, "Comparison of psychosocial distress in areas with different COVID-19prevalence in Korea", Front Psychiatry, 11, pp.593105~ (2020)
2. Ryu S, "Network study of responses to unusualness and psychological stress during the COVID-19 outbreak in Korea", PLOS One, 16, pp.e0246894~ (2021)
3. Mueller AL, "Why does COVID-19 disproportionately affect older people?", Aging (Albany NY), 12, pp.9959~9981 (2020)
4. Kim SW, "Using psychoneuroimmunity against COVID-19", Brain Behav Immun, 87, pp.4~5 (2020)
5. Yao H, "Patients with mental health disorders in the COVID-19 epidemic", Lancet Psychiatry, 7, pp.e21~ (2020)
6. Xiang YT, "The COVID-19 outbreak and psychiatric hospitals in China: managing challenges through mental health service reform", Int J Biol Sci, 16, pp.1741~1744 (2020)
7. Sung-Wan Kim, "Physical Health Literacy and Health-related Behaviors in Patients with Psychosis", Clinical Psychopharmacology and Neuroscience, 17(2), pp.279~287 (2019), 대한정신약물학회[DOI]
8. Mazereel V, "COVID-19 vaccination for people with severe mental illness: why, what, and how?", Lancet Psychiatry, 8, pp.444~450 (2021)
9. Pinkham AE, "COVID-19-related psychological distress and engagement in preventative behaviors among individuals with severe mental illnesses", NPJ Schizophr, 7, pp.7~ (2021)
10. Lerner AM, "Preventing the spread of SARSCoV-2 with masks and other “low-tech” interventions", JAMA, 324, pp.1935~1936 (2020)
11. Jung HR, "Factors associated with mask wearing among psychiatric inpatients during the COVID-19 pandemic", Schizophr Res, 228, pp.235~236 (2021)
12. 이유리, "The Relationships among Media Usage regarding COVID-19, Knowledge about Infection, and Anxiety: Structural Model Analysis", Journal of Korean Medical Science, 35(48), pp.1~11 (2020), 대한의학회[DOI]
13. Barlati S, "Schizophrenia during the COVID-19pandemic", Curr Opin Psychiatry, 34, pp.203~210 (2021)
14. Wang Q, "Increased risk of COVID-19 infection and mortality in people with mental disorders : analysis from electronic health records in the United States", World Psychiatry, 20, pp.124~130 (2021)
15. Nemani K, "Association of psychiatric disorders with mortality among patients with COVID-19", JAMA Psychiatry, 78, pp.380~386 (2021)
16. Fond G, "Association between mental health disorders and mortality among patients with COVID-19 in 7 countries: a systematic review and meta-analysis", JAMA Psychiatry, pp.e212274~ (2021)
17. Vai B, "Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis", Lancet Psychiatry, 8, pp.797~812 (2021)
18. Barcella CA, "Severe mental illness is associated with increased mortality and severe course of COVID-19", Acta Psychiatr Scand, 144, pp.82~91 (2021)
19. Tzur Bitan D, "COVID-19 prevalence and mortality among schizophrenia patients : a large-scale retrospective cohort study", Schizophr Bull, 47, pp.1211~1217 (2021)
20. Tzur Bitan D, "COVID-19 hospitalisation, mortality, vaccination, and postvaccination trends among people with schizophrenia in Israel: a longitudinal cohort study", Lancet Psychiatry, 8, pp.901~908 (2021)
21. Lee SW, "Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: a nationwide cohort study", Lancet Psychiatry, 7, pp.1025~1031 (2020)
22. Shinn AK, "Perspectives on the COVID-19 pandemic and individuals with serious mental illness", J Clin Psychiatry, 81, pp.20com13412~ (2020)
23. Dickerson F, "Cigarette smoking by patients with serious mental illness, 1999-2016: an increasing disparity", Psychiatr Serv, 69, pp.147~153 (2018)
24. Steiner J, "Acute schizophrenia is accompanied by reduced T cell and increased B cell immunity", Eur Arch Psychiatry Clin Neurosci, 260, pp.509~518 (2010)
25. Wang AK, "Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients:comparisons between schizophrenia, bipolar disorder, and depression", Schizophr Bull, 44, pp.75~83 (2018)
26. Correll CU, "Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder", World Psychiatr, 14, pp.119~136 (2015)
27. Villasante-Tezanos AG, "Pneumonia risk : approximately one-third is due to clozapine and two-thirds is due to treatment-resistant schizophrenia", Acta Psychiatr Scand, 142, pp.66~67 (2020)
28. Ferraris A, "The effect of antipsychotic treatment on recurrent venous thromboembolic disease: a cohort study", J Clin Psychiatry, 80, pp.18m12656~ (2019)
29. Reilev M, "Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARSCoV-2 in Denmark: a nationwide cohort", Int J Epidemiol, 49, pp.1468~1481 (2020)
30. Poblador-Plou B, "Baseline chronic comorbidity and mortality in laboratory-confirmed COVID-19 cases: results from the PRECOVID study in Spain", Int J Environ Res Public Health, 17, pp.1~14 (2020)
31. Nemani K, "Association between antipsychotic use and COVID-19 mortality among people with serious mental illness" (2021), JAMA Psychiatry
32. Perry RJ, "Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study", Lancet, 398, pp.1147~1156 (2021)
33. Kim HW, "Patients with acute myocarditis following mRNA COVID-19 vaccination", JAMA Cardiol, pp.e212828~ (2021)
34. Lorenz RA, "Factors associated with influenza vaccination decisions among patients with mental illness", Int J Psychiatry Med, 46, pp.1~13 (2013)
35. Tzur Bitan D, "Patients with schizophrenia are under-vaccinated for COVID-19 : a report from Israel", World Psychiatry, 20, pp.300~301 (2021)
36. Miles LW, "Adult vaccination rates in the mentally ill population: an outpatient improvement project", J Am Psychiatr Nurses Assoc, 26, pp.172~180 (2020)
37. Ettman CK, "Prevalence of depression symptoms in US adults before and during the COVID-19 pandemic", JAMA Netw Open, 3, pp.e2019686~ (2020)
38. Kim SW, "Risk and protective factors of depression in the general population during the COVID-19 epidemic in Korea", BMC Psychiatry, 21, pp.445~ (2021)
39. Lee YR, "Differential pathways of the effects of COVID-19-related stress and fear on depression between patients with schizophrenia and the general population" (2021), NPJ Schizophr
40. Brown E, "The potential impact of COVID-19 on psychosis: a rapid review of contemporary epidemic and pandemic research", Schizophr Res, 222, pp.79~87 (2020)
41. Muruganandam P, "COVID-19 and severe mental illness: impact on patients and its relation with their awareness about COVID-19", Psychiatry Res, 291, pp.113265~ (2020)
42. Kim SW, "Clinical and psychosocial factors associated with depression in patients with psychosis according to stage of illness", Early Interv Psychiatry, 14, pp.44~52 (2020)
43. Ryu Seunghyong, "Current and Future Trends in Hospital Utilization of Patients With Schizophrenia in Korea: A Time Series Analysis Using National Health Insurance Data", PSYCHIATRY INVESTIGATION, 18(8), pp.795~800 (2021), 대한신경정신의학회[DOI]
44. Ryu S, "Decline in hospital visits by patients with schizophrenia early in the COVID-19 outbreak in Korea" (2021), Clin Psychopharmacol Neurosci
45. Zhand N, "Implications of the COVID-19 pandemic for patients with schizophrenia spectrum disorders: narrative review", BJPsych Open, 7, pp.e35~ (2021)
46. 김성완, "조현병 환자를 위한 정신사회적 중재", 신경정신의학, 57(3), pp.235~243 (2018), 대한신경정신의학회[DOI]
47. Siskind D, "Consensus statement on the use of clozapine during the COVID-19 pandemic", J Psychiatry Neurosci, 45, pp.222~223 (2020)
48. "Clozapine drug monitoring during COVID-19 for stable adult patients"[URL]
49. Seong Hoon Jeong, "Challenges in Prescribing Clozapine in the Era of COVID-19: A Review Focused on Immunological Implications", Clinical Psychopharmacology and Neuroscience, 19(3), pp.411~422 (2021), 대한정신약물학회[DOI]
50. Taipale H, "20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)", World Psychiatry, 19, pp.61~68 (2020)
51. de Leon J, "Clozapine is strongly associated with the risk of pneumonia and inflammation", Gen Psychiatr, 33, pp.e100183~ (2020)
52. Shah RR, "Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes : hypothesis with implications for personalized medicine", Drug Metab Dispos, 43, pp.400~410 (2015)
53. Clark SR, "Elevated clozapine levels associated with infection: a systematic review", Schizophr Res, 192, pp.50~56 (2018)
54. Ostuzzi G, "Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations", BMC Med, 18, pp.466~481 (2020)
55. Bishara D, "Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents", Ther Adv Psychopharmacol, 10, pp.2045125320935306~ (2020)
56. "Long-acting injectable (LAI)antipsychotics–How to manage patients on long-acting injectable (LAI, or depot) antipsychotics during the COVID-19 pandemic"[URL]
57. Kim SW, "Effectiveness of switching to long-acting injectable aripiprazole in patients with recent-onset and chronic schizophrenia" (2021), Clin Psychopharmacol Neurosci
58. Lee Ju-Yeon, "Factors Associated With a Negative Emotional Response to News Media and Nationwide Emergency Text Alerts During the COVID-19 Outbreak in Korea", PSYCHIATRY INVESTIGATION, 18(9), pp.825~830 (2021), 대한신경정신의학회[DOI]
59. Kozloff N, "The COVID-19 global pandemic : implications for people with schizophrenia and related disorders", Schizophr Bull, 46, pp.752~757 (2020)
60. Kopelovich SL, "Remote CBT for psychosis during the COVID-19 pandemic : challenges and opportunities", Community Ment Health J, 57, pp.30~34 (2021)
61. O’Donoghue B, "The need for early intervention for psychosis to persist throughout the COVID-19 pandemic and beyond", Ir J Psychol Med, 38, pp.214~219 (2021)
62. Ju-Wan Kim, "Telephone based Interventions for Psychological Problems in Hospital Isolated Patients with COVID-19", Clinical Psychopharmacology and Neuroscience, 18(4), pp.616~620 (2020), 대한정신약물학회[DOI]
63. 김성완, "조현병 환자의 인지행동치료 기반 사례관리를 위한 스마트폰 애플리케이션 개발", 대한조현병학회지, 19(1), pp.10~16 (2016), 대한조현병학회
64. Kim SW, "Development and feasibility of smartphone application for cognitive behavioural case management of individuals with early psychosis", Early Interv Psychiatry, 12, pp.1087~1093 (2018)
65. "Mindlink YouTube channel", 마인드링크[URL]
66. 2020 Gwangju Mental Health and Welfare Commission Annual report, "Kim SW", Gwangju Mental Health and Welfare Commission, ~ (2020)
67. Ryu S, "Trends in suicide deaths before and after the COVID-19 outbreak in Korea" (2021), Front Psychiatry
68. Kim SW, "Mindlink : a stigma-free youth-friendly community-based early intervention centre in Korea", Early Interv Psychiatry, 15, pp.1389~1394 (2021)
69. Sham PC, "Schizophrenia following pre-natal exposure to influenza epidemics between 1939 and 1960", Br J Psychiatry, 160, pp.461~466 (1992)

관련 논문AI추천